Genmab A/S (GMAB): A Bull Case Theory [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
Genmab A/S's share was trading at $33.87 as of January 13th. GMAB's trailing and forward P/E were 14.83 and 12.58, respectively according to Yahoo Finance. Photo by National Cancer Institute on Unsplash Genmab is a leading biotechnology company focused on antibody therapeutics for cancer and serious diseases, operating a royalty driven, asset light business model that delivers high margin, high quality earnings. Alongside Regeneron, it ranks as a top two player in antibody therapeutics, but offers a more attractive risk reward profile by partnering with large pharmaceutical companies rather than fully funding development internally. Genmab's core economic moat is built on four proprietary antibody platforms that enable rapid and precise drug development, which have already produced patented, globally approved therapies such as Darzalex, Kesimpta, and EPKINLY. The business is overwhelmingly driven by recurring royalties, which account for 80.6% of revenue from partner drug sales,
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Business Wire
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)GlobeNewswire
- Is Genmab (CPSE:GMAB) Pricing Reflect Its Recent Biotech Momentum And DCF Upside Potential [Yahoo! Finance]Yahoo! Finance
- Anthropic unveils Claude for Healthcare, expands life science features, and partners with HealthEx to let users connect medical records [Fortune]Fortune